Clean Yield Group Acquires 986 Shares of Edwards Lifesciences Co. (NYSE:EW)

Clean Yield Group increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4,108.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,010 shares of the medical research company’s stock after purchasing an additional 986 shares during the period. Clean Yield Group’s holdings in Edwards Lifesciences were worth $75,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Edwards Lifesciences by 239.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after buying an additional 2,606,950 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after buying an additional 1,043,484 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $39,628,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $1.66 during midday trading on Monday, reaching $71.76. 3,260,834 shares of the company traded hands, compared to its average volume of 3,822,875. The firm’s fifty day moving average price is $71.64 and its two-hundred day moving average price is $71.92. The firm has a market capitalization of $42.32 billion, a price-to-earnings ratio of 10.35, a price-to-earnings-growth ratio of 3.61 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.59 earnings per share. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,500 shares of company stock valued at $2,508,350. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the subject of a number of recent research reports. Morgan Stanley reissued an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 11th. Barclays upped their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Finally, Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.